Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Phase 3CompletedNCT00309062

Allergopharma GmbH & Co. KG

Overview

Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Birch Pollen Allergy

Interventions

Recombinant birch pollenBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive Skin Prick Test reaction to birch pollen * Positive RAST result to birch pollen * Positive Provocation Test result to birch pollen Exclusion Criteria: * Serious chronic diseases * Other perennial allergies

Locations (1)

Allergopharma GmbH & Co. KG

Reinbek, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.